Medibio Enters Into an Agreement with Otsuka Pharmaceutical Development & Commercialization, Inc.
Monday, October 09, 2017
Medibio Limited, is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions, is pleased to announce it has entered into an agreement with Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka).
Medibio will apply its advanced proprietary analytic platform to Otsuka clinical data to characterize key circadian, autonomic, and sleep biomarkers related to serious mental illness. Under the terms of the agreement, Medibio will receive payments for services provided.
“We are excited about working with Otsuka, a recognized worldwide leader in treatments for serious mental illness, to advance our mutual understanding of the biology that underpins mental illness, with the goal of improving outcomes,” says Medibio CEO and Managing Director Jack Cosentino. “We look forward to a long and fruitful collaboration.”
